XML 68 R57.htm IDEA: XBRL DOCUMENT
v3.23.3

Collaborative and Other Relationships (Details) $ in Thousands |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Nov. 05, 2019 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) dose | Sep. 30, 2022 USD ($)
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Revenues |  | $ 86,742 | $ 75,827 | $ 238,011 | $ 191,282
Torii Pharmaceutical Co. |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Revenues | $ 22,000 |  |  |  |
Potential milestone payments receivable if regulatory approval before specified date | $ 15,000 |  |  |  |
Maximum customary reduction on royalty rate | 50.00% |  |  |  |
Royalty payments receivable, expiration term from first commercial (in years) | 10 years |  |  |  |
Torii Pharmaceutical Co. | Minimum |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Royalty rate if maintains sakigake designation | 20.00% |  |  |  |
Torii Pharmaceutical Co. | Maximum |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Royalty rate if maintains sakigake designation | 40.00% |  |  |  |
U.S. Department of Health and Human Services, net |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Contract term (in years) |  |  |  | 5 years |
U.S. Department of Health and Human Services, net | Outside of U.S. |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Maximum number of products, doses | dose |  |  |  | 50,000 |
Number of product delivered, doses | dose |  |  |  | 49,980 |

X
- Definition Period of time between the contract date and its expiration. + References No definition available. + Details
Name: | bcrx_ContractTerm
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum percentage of customary reductions allowed on royalty rate. + References No definition available. + Details
Name: | bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix: | bcrx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Information on the maximum number of doses of RAPIVAB permitted under the contract. + References No definition available. + Details
Name: | bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Product Delivered, Doses + References No definition available. + Details
Name: | bcrx_NumberOfProductDeliveredDoses
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of potential milestone payments receivable if regulatory approval is granted. + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The expiration term of the royalty payments from first commercial date. + References No definition available. + Details
Name: | bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review. + References No definition available. + Details
Name: | bcrx_RoyaltyRateIfMaintainsSakigakeDesignation
Namespace Prefix: | bcrx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcrx_RAPIVABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |